huge knowledge gaps in pediatric hypertension from pubmed.ncbi.nlm.nih.gov/35570999/ in @kireports.bsky.social @rahulchanchlani.bsky.social at @hypertensioncanada.bsky.social #CHC25

Rahul @rahulchanchlani.bsky.social starts off with a bang Hypertension in Children Congrats for the young Investigator too! @hypertensioncanada.bsky.social #CHC25

And his conclusions! Excellent overview of really old to the rapidly emerging field of hypertension drugs @drjmluther.bsky.social at @hypertensioncanada.bsky.social #CHC25

How about the siRNA (hot off the press from yesterday's @jama.com ) Zilebesiran summary evidence @drjmluther.bsky.social at @hypertensioncanada.bsky.social #CHC25

The summary of the data on ASIs so far @drjmluther.bsky.social at @hypertensioncanada.bsky.social #CHC25

The details of the existing ASIs in development Note the selectivity of Bax/Lorun/Vica -drostats But also the half life, Bax > Lorun > Vica @drjmluther.bsky.social at @hypertensioncanada.bsky.social #CHC25

After covering Aprocitentan (see www.nephjc.com/news/aprocit...) @drjmluther.bsky.social moves on to Aldo synthase inhibitors This is his take on the potential role of ASIs #NephJC chat on Lorundrostat: www.nephjc.com/news/advance... #CHC25 @hypertensioncanada.bsky.social

This is a fantastic table of all BP drug classes approval over time We have come a long way @drjmluther.bsky.social at @hypertensioncanada.bsky.social #CHC25

diastolic hypertension and risk of aortic dissection - note the relative risk scales! @drjmluther.bsky.social at @hypertensioncanada.bsky.social #CHC25

Plenary at @hypertensioncanada.bsky.social with @drjmluther.bsky.social on new drugs He starts of with the really old drugs! #CHC25